Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKesson
Boehringer Ingelheim
McKinsey
Dow
Merck

Last Updated: November 28, 2021

DrugPatentWatch Database Preview

THEOPHYLLINE Drug Patent Profile


Email this page to a colleague

« Back to Dashboard

Which patents cover Theophylline, and what generic alternatives are available?

Theophylline is a drug marketed by Cent Pharms, Hospira, Inwood Labs, Sandoz, Kv Pharm, Scherer Rp, Alpharma Us Pharms, Cenci, Chartwell Rx, Halsey, Pharm Assoc, Precision Dose, Roxane, Taro, Wockhardt, Lannett Co Inc, Tris Pharma Inc, Able, Alembic Pharms Ltd, Glenmark Generics, Glenmark Pharms Ltd, Heritage Pharma, Nostrum Labs Inc, Rhodes Pharms, B Braun, Baxter Hlthcare, and Hospira Inc. and is included in forty-four NDAs.

The generic ingredient in THEOPHYLLINE is theophylline. There are thirty-six drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the theophylline profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Theophylline

A generic version of THEOPHYLLINE was approved as theophylline by RHODES PHARMS on September 1st, 1982.

  Free Forever Trial

Drug patent expirations by year for THEOPHYLLINE
Drug Prices for THEOPHYLLINE

See drug prices for THEOPHYLLINE

Drug Sales Revenue Trends for THEOPHYLLINE

See drug sales revenues for THEOPHYLLINE

Recent Clinical Trials for THEOPHYLLINE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of California, Los AngelesEarly Phase 1
Novartis PharmaceuticalsPhase 2
Industria FarmacĂȘutica Health MedsPhase 4

See all THEOPHYLLINE clinical trials

Pharmacology for THEOPHYLLINE
Drug ClassMethylxanthine

US Patents and Regulatory Information for THEOPHYLLINE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Hospira Inc THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER theophylline INJECTABLE;INJECTION 019211-003 Dec 14, 1984 DISCN Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
Heritage Pharma THEOPHYLLINE theophylline TABLET, EXTENDED RELEASE;ORAL 089807-001 Apr 30, 1990 DISCN No No ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
Able THEOPHYLLINE theophylline TABLET, EXTENDED RELEASE;ORAL 040543-001 Apr 27, 2004 DISCN No No ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
Rhodes Pharms THEOPHYLLINE theophylline TABLET, EXTENDED RELEASE;ORAL 040086-001 Apr 15, 1996 AB RX No No ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Express Scripts
Merck
AstraZeneca
McKesson
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.